

Consolidated Financial Statements
(In Canadian dollars)

01 COMMUNIQUE LABORATORY INC.

Years ended October 31, 2021 and 2020

Audit. Tax. Advisory.

Independent Auditor's Report

To the Shareholders of 01 Communique Laboratory Inc.

Opinion

We have audited the consolidated financial statements of 01 Communique Laboratory Inc. and its subsidiaries (the "Company"), which comprise the consolidated statements of financial position as at October 31, 2021 and 2020, and the consolidated statements of operations and comprehensive loss, consolidated statements of changes in shareholders' equity and consolidated statements of cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as at October 31, 2021 and 2020 and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with International Financial Reporting Standards ("IFRS").

Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the consolidated financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada. We have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

Management is responsible for the other information. The other information comprises Management's Discussion and Analysis [and the information, other than the consolidated financial statements and our auditor's report thereon, included in the Annual Report.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

We obtained Management's Discussion and Analysis prior to the date of this auditor's report. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRS, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risks of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner of the audit resulting in this independent auditor's report is Jessica Glendinning.

McGovern Hurley LLP



**Chartered Professional Accountants
Licensed Public Accountants**

Toronto, Ontario
January 12, 2022

01 COMMUNIQUE LABORATORY INC.

Consolidated Statements of Financial Position
(In Canadian dollars)

As at October 31, 2021 and 2020

	2021	2020
Assets		
Current assets:		
Cash	\$ 994,924	\$ 962,337
Guaranteed investment certificate (note 4)	-	60,000
Accounts receivable (note 2(a))	205,507	202,974
Prepaid expenses and other assets	31,743	25,343
Total current assets	1,232,174	1,250,654
Property and equipment (note 5)	125,584	35,253
Total assets	\$ 1,357,758	\$ 1,285,907

Liabilities and Shareholders' Equity

Current liabilities:		
Accounts payable and accrued liabilities (notes 14, 15)	\$ 182,354	\$ 151,111
Deferred revenue	6,502	7,679
Current portion of lease liability (note 6)	42,532	18,704
Total current liabilities	231,388	177,494
Non-current liabilities:		
Lease liability (note 6)	66,915	-
Canadian emergency business account loan (note 17)	40,000	-
Total liabilities	338,303	177,494
Shareholders' equity:		
Share capital (note 8(a))	43,963,582	43,395,752
Contributed surplus (note 8 (c))	5,890,297	5,717,636
Warrants (note 8(c))	93,533	266,135
Deficit	(48,927,957)	(48,271,110)
Total shareholders' equity	1,019,455	1,108,413
Total liabilities and shareholders' equity	\$ 1,357,758	\$ 1,285,907

Contingencies (note 15)

See accompanying notes to consolidated financial statements.

On behalf of the Board:

William Train Director

Gary Kissack Director

01 COMMUNIQUE LABORATORY INC.

Consolidated Statements of Operations and Comprehensive Loss
(In Canadian dollars)

Years ended October 31, 2021 and 2020

	2021	2020
Revenue (note 9)	\$ 885,345	\$ 521,791
Expenses (note 16):		
Selling, general and administrative (note 14)	841,028	586,776
Research and development (note 14)	614,219	455,177
Withholding tax	86,458	50,805
	1,541,705	1,092,758
Loss before accretion on liability component of debenture, interest, other income and expense	(656,360)	(570,967)
Interest on debenture	-	(57,718)
Accretion on liability component of debenture (note 7)	-	(30,997)
Foreign exchange gain (loss)	(17,554)	675
Interest income	966	3,030
Interest expense	(3,899)	(1,191)
Government assistance (note 17)	20,000	-
Net loss for the year and comprehensive loss	(656,847)	(657,168)
Loss per common share (note 10):		
Basic	\$ (0.01)	\$ (0.01)
Diluted	\$ (0.01)	\$ (0.01)
Weighted average number of common shares outstanding (note 10):		
Basic	92,788,400	81,720,040
Diluted	92,788,400	81,720,040

See accompanying notes to consolidated financial statements.

01 COMMUNIQUE LABORATORY INC.

Consolidated Statements of Changes in Shareholders' Equity
(In Canadian dollars)

Years ended October 31, 2021 and 2020

2021	Number of shares	Share Capital	Contributed Surplus	Warrants	Deficit	Total shareholders' equity
Balance October 31, 2020	91,393,973	\$43,395,752	\$5,717,636	\$ 266,135	\$ (48,271,110)	\$ 1,108,413
Comprehensive loss for the period	-	-	-	-	(656,847)	(656,847)
Exercise of warrants (note 8 (a)(vii))	1,612,332	386,960	-	(145,110)	-	241,850
Exercise of compensation options (note 8 (a)(viii))	184,916	44,380	-	(16,642)	-	27,738
Exercise of debenture warrants (note 8 (a) (ix))	400,000	62,850	-	(10,850)	-	52,000
Exercise of stock options (note 8 (a)(x))	860,000	73,640	(30,140)	-	-	43,500
Stock based compensation expense (note 8 (b))	-	-	202,801	-	-	202,801
Balance, October 31, 2021	94,451,221	\$43,963,582	\$5,890,297	\$ 93,533	\$ (48,927,957)	\$ 1,019,455

2020	Number of Shares	Share Capital	Contributed Surplus	Warrants	Compensatio n Options	Deficit	Total shareholders' Equity
Balance, October 31, 2019	80,235,472	\$41,414,233	\$5,668,916	\$598,247	\$ 99,200	\$(47,613,942)	\$ 166,654
Comprehensive loss	-	-	-	-	-	(657,168)	(657,168)
Equity financing (note 8(a)(i))	1,683,334	120,029	-	71,533	-	-	191,562
Exercise of warrants (note 8(a)(ii))	5,258,500	1,211,540	-	(422,765)	-	-	788,775
Exercise of compensation options (note 8(a)(iii))	1,200,000	239,200	-	-	(99,200)	-	140,000
Cancellation of debentures (note 7)	-	-	17,730	(17,730)	-	-	-
Equity portion of new debenture (note 7)	-	-	-	21,700	-	-	21,700
Exercise of debenture warrants (note 8(a)(iv))	400,000	62,850	-	(10,850)	-	-	52,000
Debenture redemption (note 8(a)(v))	766,667	174,000	-	26,000	-	-	200,000
Exercise of options (note 8(a)(vi))	1,850,000	173,900	(81,400)	-	-	-	92,500
Stock-based compensation expense (note 8(b))	-	-	112,390	-	-	-	112,390
Balance, October 31, 2020	91,393,973	\$43,395,752	\$5,717,636	\$266,135	-	\$(48,271,110)	\$ 1,108,413

See accompanying notes to consolidated financial statements.

01 COMMUNIQUE LABORATORY INC.

Consolidated Statements of Cash Flows
(In Canadian dollars)

Years ended October 31, 2021 and 2020

	2021	2020
Cash provided by (used in):		
Operating activities:		
Comprehensive loss for the year	\$ (656,847)	\$ (657,168)
Adjustments to reconcile loss for the year to net cash flows from operating activities:		
Depreciation of property and equipment	7,214	5,840
Amortization of right-of-use asset (note 1(o))	45,517	44,244
Stock-based compensation expense	202,801	112,390
Accretion on liability portion of debenture	-	30,997
Government assistance income	(20,000)	-
Change in non-cash operating working capital (note 11)	21,133	(112,217)
Total cash used in operating activities	(400,182)	(575,914)
Financing activities:		
Exercise of stock options (note 8(a)(x))	43,500	92,500
Exercise of warrants (note 8(c))	241,850	788,775
Exercise of compensation options (note 8(d))	27,738	140,000
Exercise of debenture warrants (note 8(c))	52,000	52,000
Redemption of debenture (note 7)	-	(200,000)
Proceeds from private placement (note 8(a)(i))	-	202,000
Cash share issuance costs (note 8(a)(i))	-	(10,438)
Proceeds from Canadian emergency business account loan	60,000	-
Lease payments made	(43,891)	(44,879)
Total cash provided by financing activities	381,197	1,019,958
Investing activities:		
Proceeds from guaranteed investment certificate	60,000	360,000
Purchase of guaranteed investment certificate	-	(120,000)
Purchase of property and equipment	(8,428)	(5,419)
Total cash used in investing activities	51,572	234,581
Increase in cash	32,587	678,625
Cash, beginning of year	962,337	283,712
Cash, end of year	\$ 994,924	\$ 962,337
Supplemental information:		
Issuance of compensation warrants	\$ -	\$ 4,200
Issuance of shares and warrants in settlement of debenture	\$ -	\$ 200,000

See accompanying notes to consolidated financial statements.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

01 Communique Laboratory Inc. (the "Company") was incorporated on October 7, 1992 under the laws of Ontario. The Company's cybersecurity business unit focuses on its IronCAP™ patent-pending cryptographic system. The Company's remote access business unit focuses on its I'm InTouch suite of secure remote access services and products.

The Company's head office is located at 789 Don Mills Road, Suite 700, Toronto, Ontario M3C 1T5 and its common shares are traded on the TSX Venture Exchange ("TSX-V") under the symbol ONE and quoted on the OTCQB market in the United States under the symbol OONEF.

1. Significant Accounting Policies:

The accounting policies set out below have been applied consistently to all years presented in these consolidated financial statements, unless otherwise indicated:

(a) Statement of compliance:

These consolidated financial statements, including comparatives, are prepared by management in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") effective for the Company's reporting for the year ended October 31, 2021. These consolidated financial statements reflect management's best estimates and judgment based on information currently available.

These consolidated financial statements were authorized for issue by the Board of Directors on January 12, 2022.

(b) Basis of presentation:

These consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, 01 Communique (GP) Inc. and 01 Communique Laboratory Hong Kong Limited. Intercompany transactions and balances are eliminated on consolidation.

Subsidiaries consist of entities over which the Company is exposed to, or has rights to, variable returns as well as the ability to affect those returns through the power to direct the relevant activities of the entity. Generally, the Company has a shareholding of more than one half of the voting rights in its subsidiaries. The effects of potential voting rights that are currently exercisable are considered when assessing whether control exists. Subsidiaries are fully consolidated from the date control is transferred to the Company, and are deconsolidated from the date control ceases. The financial statements include all the assets, liabilities, revenues, expenses and cash flows of the Company and its subsidiaries after eliminating inter-entity balances and transactions.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

The consolidated financial statements have been prepared on the historical cost basis, except for certain items which may be accounted for at fair value as further discussed in subsequent notes, using the Significant accounting policies and measurement bases summarized below.

The consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

The consolidated financial statements are presented in Canadian dollars, which is the Company's functional currency.

Presentation of the consolidated statements of financial position differentiates between current and non-current assets and liabilities. The consolidated statements of operations and comprehensive loss are presented using the functional classification for expenses.

These consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities in the normal course of business. The Company has sustained substantial losses and negative cash flows from operations in recent years and its ability to continue as a going concern is dependent on the Company's ability to generate future profitable operations and cash flows and/or obtain additional financing.

Should the Company not be able to generate sufficient cash flows to become profitable in the future and generate sufficient working capital to fund operations, it will become necessary to secure additional sources of financing. However, there can be no assurances that any such financing will be available to the Company on acceptable terms or at all. These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and, therefore, be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in these consolidated financial statements.

(c) Revenue recognition:

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered in accordance with the terms of the arrangement, fees are fixed and determinable, and collection is reasonably assured. Revenue is measured based on the consideration specified in the contract.

The Company has multiple sources of revenue, and in general, the Company recognizes revenue in accordance with the above policy. The following are the revenue sources and the specific revenue recognition criteria for these sources:

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

- (i) Revenue from software development is determined based on completion of specific performance obligations as agreed to under the terms of the agreement, provided these amounts can be measured reliably and collection is reasonably assured.
- (ii) Revenue from royalty fee agreements is recognized at the later of delivery of the software by the licensee and fulfillment of all other significant performance obligations under the terms of the underlying license agreement.
- (iii) Revenue from subscriptions and maintenance are recognized as the services are provided over the life of the contract on a straight-line basis.

To the extent payments are received before completion of specific performance obligations, the payments are reflected as deferred revenue.

- (d) Cash and cash equivalents:

Cash and cash equivalents include cash on account and short-term, highly liquid investments with original maturities of three months or less.

- (e) Property and equipment:

Property and equipment are stated at cost less accumulated depreciation and impairment losses.

The cost of an item of property and equipment consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to the profit or loss in the years in which they are incurred.

Any gain and loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized within selling, general and administrative expenses in the consolidated statements of operations.

Depreciation is calculated over the depreciable amount, which is the cost of an asset less its estimated residual value.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

Depreciation is provided on a declining balance basis over the estimated useful lives of the property and equipment at the following annual rates:

Computer systems	30%
Communications equipment	10% - 20%
Furniture and fixtures	20%
Right-of-use assets	Shorter of estimated useful life and term of lease
Leasehold improvements	Shorter of estimated useful life and term of lease

(f) Research and development:

All research costs are expensed as incurred. Software development costs are expensed as incurred unless they satisfy the criteria for capitalization and subsequent amortization. The Company has not capitalized any such development costs to date. Expenditures on internally developed software programs are capitalized if it can be demonstrated that:

- It is technically feasible to develop the product and for it to be sold;
- Adequate resources are available to complete the development;
- There is an intention to complete and sell the product;
- There is the ability to use or sell the product;
- Sale of the product will generate future economic benefits; and
- Expenditure on the project can be measured reliably.

Development expenses are charged to operations as incurred unless such costs meet the criteria for capitalization and amortization.

(g) Foreign exchange translation:

The Company's functional and presentation currency is the Canadian dollar. The functional currency of the Company's subsidiary is the Canadian dollar. Monetary assets and liabilities that are denominated in foreign currencies are translated into Canadian dollars at the year-end exchange rates. Non-monetary assets and liabilities denominated in foreign currencies are translated at their historical exchange rates. Revenue and expenses are translated at average rates of exchange for the month of the transaction. All of the exchange gains or losses resulting from these transactions are recognized in operations.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

(h) Stock-based compensation:

The fair value of each stock option granted to employees and others providing similar services is estimated on the date of the grant using the Black-Scholes option-pricing model and expensed over the vesting period.

Equity-settled share-based compensation transactions with parties other than employees are measured at the fair value of the goods or services received, except where fair value cannot be estimated reliably, in which case they are measured at the fair value of the equity instruments granted, measured at the date the entity obtains the goods or the counterparty renders the services.

Stock-based compensation expense is recognized so that each tranche in a stock option award with graded vesting is considered a separate grant with a different vesting date and fair value. No compensation expense is recognized for stock options that are forfeited if the grantee fails to satisfy the service requirement for vesting. The amount recognized is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that vest.

(i) Loss per share:

Basic loss per share is computed using the weighted average number of common shares outstanding during the years. Diluted loss per share is computed using the weighted average number of common and potential common shares outstanding during the years, if dilutive. The diluted loss per share calculation assumes that any proceeds from the exercise of dilutive stock options and warrants would be used to repurchase common shares at the average market price during the period, with the incremental number of shares being included in the denominator of the diluted loss per share calculation.

(j) Income taxes:

Income tax expense comprises current and deferred tax. Current and deferred tax are recognized in the consolidated statements of operations, except to the extent that they relate to a business combination, or items recognized directly in equity or in other comprehensive loss.

Current tax is the expected tax payable or receivable based on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to taxes payable in respect of previous years.

Deferred tax assets and liabilities are recognized for the future income tax consequences attributable to differences between the consolidated financial statements' carrying amounts

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted or substantively enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized.

(k) Provisions:

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Examples could include:

Legal claims:

In the normal course of operations, the Company may be subject to litigation claims from customers, suppliers, patent holders, former employees and others. A provision is recognized when the Company determines the probability that the event will occur is greater than the probability that it will not. The Company regularly reviews any outstanding claims it may have to see if they meet the criteria. A provision is calculated based on management's best estimate of a probable outflow of economic resources.

(l) Financial instruments:

The Company recognizes a financial asset or a financial liability when it becomes a party to the contractual provisions of the instrument. Purchases or sales of financial assets that require delivery of assets within the time frame generally established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the company commits to purchase or sell the asset. The Company classifies its financial assets and financial liabilities at initial recognition into the following categories, in accordance IFRS 9.

(i) Financial Assets and Liabilities at Fair Value through Profit or Loss ("FVTPL")

These financial assets are designated upon initial recognition on the basis that they are evaluated on a fair value basis in accordance with risk management and investment strategies of the Company. The Company does not currently classify any financial assets or liabilities as FVTPL.

Subsequent to initial recognition, financial assets and financial liabilities at FVTPL are measured at fair value. Gains and losses arising from changes in the fair value of the

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

'financial assets or financial liabilities at FVTPL' category are presented in the consolidated statement of operation within 'changes in unrealized appreciation (depreciation)' in the period in which they arise. Interest and dividends earned or paid on these instruments are recorded separately in interest revenue or expense and dividend revenue or expense.

(ii) Financial Assets at Fair Value Through Other Comprehensive Income ("FVOCI")

Financial assets measured at FVOCI are non-derivative financial assets that are not held for trading and the Company has made an irrevocable election at the time of initial recognition to measure the assets at FVOCI. The Company currently does not measure any financial assets at FVOCI.

After initial measurement, investments measured at FVOCI are subsequently measured at fair value with unrealized gains or losses recognized in other comprehensive income or loss in the consolidated statements of comprehensive income (loss). When the investment is sold, the cumulative gain or loss remains in accumulated other comprehensive income or loss and is not reclassified to profit or loss. Dividends from such investments are recognized in other income in the consolidated statements of operations when the right to receive payments is established.

(iii) Financial Assets at Amortized Cost

This category is comprised of non-derivative financial assets with fixed or determinable payments, including loans and receivables that are not quoted in an active market and cash and cash-equivalents. These financial assets are initially measured at fair value and subsequently measured at amortized cost. Transaction costs are included in the initial carrying amount of the asset. The Company includes its cash and cash equivalents, guaranteed investment certificate and accounts receivable in this category.

(iv) Financial Liabilities at Amortized Cost

This category includes all financial liabilities, other than those classified at FVTPL. Financial liabilities classified as other financial liabilities are initially measured at fair value and subsequently measured at amortized cost. Transaction costs are included in the initial carrying amount of the liability. The Company includes accounts payable and accrued liabilities and the Canadian emergency business account loan in this category.

Impairment of Financial Assets

The Company's only financial assets subject to impairment are other accounts receivable, which are measured at amortized cost. The Company has elected to apply the simplified approach to impairment as permitted by IFRS 9, which requires the expected lifetime loss to be recognized at the time of initial recognition of the receivable. To measure estimated credit losses, accounts receivable have been grouped based on shared credit risk characteristics,

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

including the number of days past due. An impairment loss is reversed in subsequent periods if the amount of the expected loss decreases and the decrease can be objectively related to an event occurring after the initial impairment was recognized.

Compound Financial Instruments

The components of compound financial instruments are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. The liability component of a compound financial instrument is recognized initially at the estimated fair value of a similar liability that does not have an equity component. The equity component is recognized initially at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not re-measured subsequent to initial recognition.

(m) Government assistance

Government grants are not recognized until there is reasonable assurance that the Company will comply with the conditions attached to them and that the grants will be received. The benefit of a government loan at a below-market rate of interest is treated as a government grant, measured as the difference between proceeds received and the fair value of the loan based on prevailing market interest rates.

Government grants whose primary condition is that the Company should purchase, construct or otherwise acquire non-current assets are recognized as a reduction of the non-current assets in the consolidated statement of financial position, and transferred to the consolidated statement of operations on a systematic and rational basis over the useful lives of the related assets. Other government grants are recognized as a reduction of the related expenses over the periods necessary to match them with the costs for which they are intended to compensate, on a systematic basis. Government grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Company with no future related costs are recognized in the consolidated statement of operations in the period in which they become receivable.

(n) Leases

At inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

The Company recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, based on the initial amount of the lease liability. The asset is depreciated to the earlier of the end of the useful life of the right-of-use asset or the lease term using the straight-line method as this most closely reflects the expected pattern of consumption of the future economic benefits. The lease term can include periods covered by an option to extend if the Company is reasonably certain to exercise that option providing the lease has such a provision. In addition, the right-of-use asset is periodically adjusted for certain remeasurements of the lease liability, if required.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. The lease liability is measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

The Company has elected to apply the practical expedient not to recognize right-of-use assets and lease liabilities for (1) short-term leases, that have a lease term of 12 months or less, as well as for (2) leases of low value assets. The lease payments associated with these leases are recognized as expenses on a straight-line basis over the lease term.

(o) Measurement uncertainty:

The preparation of consolidated financial statements prepared in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of assets and liabilities and disclose contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the years. Actual results could differ from those estimates. Management must also make estimates and judgements about future results of operations in assessing recoverability of assets and the value of liabilities. These judgements, estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the years in which the estimates are revised and in any future years affected.

Critical judgements and estimates used in the preparation of the consolidated financial statements include the following:

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

Going concern

The Company's ability to continue its ongoing and planned software development activities and to continue operations as a going concern is dependent on the Company achieving profitable operations and/or the ability to obtain external financing from time to time.

Income, value added, withholding and other taxes

The Company is subject to income, value added, withholding and other taxes. Significant judgment is required in determining the Company's provisions for taxes. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. The Company recognizes liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. The determination of the Company's income, value added, withholding and other tax liabilities requires interpretation of complex laws and regulations. The Company's interpretation of taxation law as applied to transactions and activities may not coincide with the interpretation of the tax authorities. All tax related filings are subject to government audit and potential reassessment subsequent to the financial statement reporting period. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the tax related accruals and deferred income tax provisions in the period in which such determination is made.

Share-based payments and warrants

Management estimates the values for share-based payments and warrants using market-based valuation techniques. The fair value of the market-based share awards is determined at the date of grant using generally accepted valuation techniques. Assumptions are made and judgment used in applying valuation techniques. These assumptions and judgments include estimating the future volatility of the stock price, expected dividend yield, future employee turnover rates and future employee stock option exercise behaviors and corporate performance. Such judgments and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates.

Development costs qualifying for capitalization

In assessing whether development costs qualify for capitalization, management makes judgments and estimates related to expectations of technical feasibility in completing the project, the probability of future economic benefits, the availability of adequate technical and financial resources to complete the development, the ability to reliably measure the costs, and whether the Company intends to complete development, and to use or sell the assets.

In making these judgments and estimates, management has assessed various sources of information, including but not limited to, criteria for the capitalization of development costs,

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

forecasted cash flows associated with the developments and with operations, in general, which are used to support whether or not the Company will have sufficient resources to complete the development of the assets. Changes in management's judgments, estimates and assumptions, could have a material effect in the future on the Company's financial position and results of operations.

Compound financial instruments

The classification of the Company's debentures required management to analyze the terms and conditions of the debentures and use judgment to assess whether these debentures are liability, equity, or a combination of the two. IAS 32 provides the criteria for management to assess these complicated financial instruments to determine their appropriate classification(s). Factors considered are, but not limited to, whether the Company has a future obligation to settle the instrument in cash or exchange other assets or liabilities, the currency of settlement and if the settlement is already known to be equity, the amount will not vary based on the Company's future share price. Estimating the liability and equity components of the debentures requires determining and making assumptions about the inherent value of the liability components including the discount rate appropriate for similar debt instruments, absent any warrants.

Government assistance and investment tax credits

The Company has applied for and received funding from certain government grants and assistance programs. Remaining funding under these grant programs, if any, will be recognized when the Company qualifies and there is reasonable assurance that the grant will be received. Government assistance and investment tax credits received are subject to government audit and potential reassessment subsequent to the reporting period. Where the final outcome of these matters is different from the amounts that were initially recorded, such differences will be recognized in operations in the period in which such determination is made.

Revenue recognition

Application of the accounting principles related to the measurement and recognition of revenue requires the Company to make judgments and estimates. Revenue arrangements may be comprised of multiple performance obligations. Judgment is required in determining the performance obligations that exist in an arrangement and the nature of these deliverables.

Discount rate used on leases

The determination of the Company's lease liabilities and right-of-use assets depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company's estimated incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

this determination. Changes in the assumptions used may have a significant effect on the Company's consolidated financial statements.

Commitments and contingencies

Refer to Note 15.

(p) Adoption of new accounting policies:

IAS 1 – Presentation of Financial Statements (“IAS 1”) and IAS 8 – Accounting Policies, Changes in Accounting Estimates and Errors (“IAS 8”) were amended in October 2018 to refine the definition of materiality and clarify its characteristics. The revised definition focuses on the idea that information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements.

During the year ended October 31, 2021, the Company adopted a number of amendments and improvements of existing standards. These included IAS 1. These new standards and changes did not have any material impact on the Company's consolidated financial statements.

(q) Recent accounting pronouncements effective January 1, 2021 and beyond:

Certain pronouncements were issued by the IASB or the IFRIC that are mandatory for accounting periods commencing on or after November 1, 2021. Many are not applicable or do not have a significant impact to the Company and have been excluded.

IFRS 10 – Consolidated Financial Statements (“IFRS 10”) and IAS 28 – Investments in Associates and Joint Ventures (“IAS 28”) were amended in September 2014 to address a conflict between the requirements of IAS 28 and IFRS 10 and clarify that in a transaction involving an associate or joint venture, the extent of gain or loss recognition depends on whether the assets sold or contributed constitute a business. The effective date of these amendments is yet to be determined, however early adoption is permitted.

IAS 1 – Presentation of Financial Statements (“IAS 1”) was amended in January 2020 to provide a more general approach to the classification of liabilities under IAS 1 based on the contractual arrangements in place at the reporting date. The amendments clarify that the classification of liabilities as current or noncurrent is based solely on a company's right to defer settlement at the reporting date. The right needs to be unconditional and must have substance. The amendments also clarify that the transfer of a company's own equity instruments is regarded as settlement of a liability, unless it results from the exercise of a conversion option meeting the definition of an equity instrument. The amendments are effective for annual periods beginning on January 1, 2023.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

IAS 37 – Provisions, Contingent Liabilities, and Contingent Assets (“IAS 37”) was amended. The amendments clarify that when assessing if a contract is onerous, the cost of fulfilling the contract includes all costs that relate directly to the contract – i.e. a full-cost approach. Such costs include both the incremental costs of the contract (i.e. costs a company would avoid if it did not have the contract) and an allocation of other direct costs incurred on activities required to fulfill the contract – e.g. contract management and supervision, or depreciation of equipment used in fulfilling the contract. The amendments are effective for annual periods beginning on January 1, 2022.

IAS 16 – Property, Plant and Equipment (“IAS 16”) was amended. The amendments introduce new guidance, such that the proceeds from selling items before the related property, plant and equipment is available for its intended use can no longer be deducted from the cost. Instead, such proceeds are to be recognized in profit or loss, together with the costs of producing those items. The amendments are effective for annual periods beginning on January 1, 2022.

2. Financial Instruments and Financial Risk Management:

(a) Financial instruments:

The Company has classified its financial instruments as follows:

	2021	2020
Financial assets:		
Financial assets measured at amortized cost:		
Cash and cash equivalents	\$ 994,924	\$ 962,337
Guaranteed investment certificate	-	60,000
Accounts receivable	205,507	202,974
Financial liabilities:		
Financial liabilities measured at amortized cost:		
Accounts payable and accrued liabilities	182,354	151,111
Canadian emergency business account loan	40,000	-

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

Accounts receivable comprise the following:

	2021	2020
Trade receivables	\$ 158,073	\$ 166,322
Investment tax credits receivable	25,000	17,500
HST receivable	22,434	19,152
	<u>\$ 205,507</u>	<u>\$ 202,974</u>

(b) Financial risk management:

(i) Overview:

The Company has exposure to credit risk, liquidity risk and market risk. The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework and reviews the Company's policies on an ongoing basis.

(a) Credit risk:

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's cash and accounts receivable. The carrying amount of financial assets represents the maximum credit exposure.

The Company's exposure to credit risk with its customers is influenced mainly by the individual characteristics of each customer. The Company generally does not require collateral for sales on credit. The Company closely monitors extensions of credit and has not experienced significant credit losses in the past. At October 31, 2021 and 2020, the Company had a nil balance in the allowance for doubtful accounts and had no material past due trade receivables.

The Company invests its cash with the objective of maintaining safety of principal and providing adequate liquidity to meet all current payment obligations. The Company invests its cash with Canadian chartered banks that are of high credit quality. Given these high credit ratings, the Company does not expect these counterparties to fail to meet their obligations.

Concentrations of credit risk:

In 2021, there was one customer that comprised 98% (2020 - 95%) of the Company's total revenue. No other customers exceeded 10% of revenue during the current or prior

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

year. The customer comprising 98% of revenue in 2020 (2020 – 95%) comprised 100% of trade receivables, as at October 31, 2021 (2020 – 100%).

(b) Liquidity risk:

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company's approach to managing liquidity is to ensure that it will have sufficient liquidity to meet its liabilities when due. To the extent that the Company does not believe it has sufficient liquidity to meet these obligations, management will consider securing additional funds through equity or debt transactions.

However, the Company has sustained substantial losses in recent years and its ability to continue as a going concern is dependent on the Company's ability to generate future profitable operations and cash flows and/or obtain additional financing, which would be contingent upon market and other conditions in the future, which are beyond the Company's control.

At October 31, 2021, the Company had financial assets, consisting of cash, guaranteed investment certificate and accounts receivable of \$1,200,431 (2020 - \$1,225,311) and financial liabilities, consisting of accounts payable and accrued liabilities and the Canadian emergency business account loan of \$222,354 (2020 - \$151,111).

The Company manages its liquidity risk by continuously monitoring forecasted and actual cash flows.

(c) Market risk:

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk is comprised of currency risk, interest rate risk and market price risk. The Company is exposed to currency risk and interest rate risk.

Currency risk:

Net monetary assets and liabilities due in U.S. dollars include accounts payable of \$23,030 (2020 – \$15,148), cash of \$568,902 (2020 - \$179,571) and accounts receivable of \$127,478 (2020 - \$126,001).

The Company reports its results in Canadian dollars. The Company markets its products in Canada, the United States ("U.S.") and other jurisdictions, including Japan. Sales to Japanese customers are primarily denominated in U.S. dollars. Substantially all of the Company's sales are in U.S. dollars. As a result, the Company is subject to currency risk from both sales made and expenses incurred in U.S. dollars. The Company does not

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

hedge the risk related to fluctuations in the exchange rate between the U.S. and the Canadian dollar from either the date of the sales transaction to the collection date due or from the date an expense is incurred in the U.S. to the date the payment is made. As at October 31, 2021, the Company had net monetary assets in U.S. dollars of \$673,351 (2020 –\$261,600). An increase or decrease in the U.S. to Canadian dollar exchange rate by 10% as at October 31, 2021 would have resulted in a gain in the amount of \$83,500 (2020 - \$38,300) or a loss of \$83,500 (2020 - \$38,300), respectively.

The Company has performed a sensitivity analysis for foreign exchange exposure over the year ended October 31, 2021. The analysis used a modeling technique that compares the U.S. dollar equivalent of all revenue and expenses incurred in U.S. dollars, at the actual exchange rate, to a hypothetical 10% movement in the foreign currency exchanges rates against the Canadian dollar, with all other variables held constant. Foreign currency exchanges rates used were based on the market rates in effect during the year ended October 31, 2021. The sensitivity analysis indicated that a hypothetical 10% movement in the foreign currency exchange rate from the Canadian dollar to the U.S. dollar would result in a change to the net loss for the year ended October 31, 2021. An increase or decrease in the U.S. to Canadian dollar exchange rate by 10% during the year ended October 31, 2021 would have resulted in a gain in the amount of \$75,700 (2020 - \$41,600) or a loss of \$75,700 (2020 - \$41,600), respectively. There can be no assurances that the above projected exchange rate change will materialize.

Interest rate risk:

The Company is exposed to interest rate risk on its fixed rate financial instruments. Fixed rate instruments subject the Company to fair value interest rate risk, as the fair value of the financial instrument fluctuates due to changes in market interest rates. Financial instruments subject to interest rate risk include demand deposits and the liability component of the debenture.

(ii) Fair values of financial instruments:

All financial instruments measured at fair value are categorized into one of three hierarchy levels, described below, for disclosure purposes. Each level is based on the transparency of the inputs used to measure the fair values of assets and liabilities:

Level 1 – Values based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets of liabilities.

Level 2 – Values based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

Level 3 – Values based on prices or valuations techniques that require inputs that are both unobservable and significant to the overall fair value measurement.

There are no financial instruments that are measured at fair value on a regular basis.

3. Capital Risk Management:

The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to fund operations and discharge liabilities as they become due. Management performs regular reviews of its forecasted cash flow requirements to ensure cash flow needs are addressed.

The Board does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company considers its capital to consist of shareholders' equity.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no significant changes in the Company's approach to capital management during the years ended October 31, 2021 and 2020.

The Company and its subsidiaries are not subject to any capital requirements imposed by a lending institution or regulatory body, other than of the TSX Venture Exchange ("TSXV") which requires adequate working capital or financial resources of the greater of (i) \$50,000 and (ii) an amount required to maintain operations and cover general and administrative expenses for a period of 6 months. As at October 31, 2021 and 2020, the Company believes it is compliant with the policies of the TSXV.

4. Guaranteed Investment Certificate:

		2021	2020
i)	One year cashable guaranteed investment certificate bearing interest at the rate of 1.4% per annum and matured February 12, 2021.	\$ -	\$ 60,000
		\$ -	\$ 60,000

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

5. Property and Equipment:

	Computer systems	Communications equipment	Furniture and fixtures and leasehold improvements	Right of Use Asset	Total
Cost					
Balance at October 31, 2019	\$ 549,516	\$ 30,281	\$ 94,805	\$ -	\$ 674,602
Additions	4,925	-	494	63,583	69,002
Dispositions	-	(26,887)	-	-	(26,887)
Balance at October 31, 2020	\$ 554,441	\$ 3,394	\$ 95,299	\$ 63,583	\$ 716,717
Additions	4,214	-	4,214	134,634	143,062
Dispositions	-	-	-	(63,583)	(63,583)
Balance at October 31, 2021	\$ 558,655	\$ 3,394	\$ 99,513	\$ 134,634	\$ 796,196
Depreciation					
Balance at October 31, 2019	\$ 537,178	\$ 27,084	\$ 94,005	\$ -	\$ 658,267
Additions	5,500	340	-	44,244	50,084
Dispositions	-	(26,887)	-	-	(26,887)
Balance at October 31, 2020	\$ 542,678	\$ 537	\$ 94,005	\$ 44,244	\$ 681,464
Additions	2,263	340	4,611	45,517	52,731
Dispositions	-	-	-	(63,583)	(63,583)
Balance at October 31, 2021	\$ 544,941	\$ 877	\$ 98,616	\$ 26,178	\$ 670,612
Carry amounts					
Balance at October 31, 2020	\$ 11,763	\$ 2,857	\$ 1,294	\$ 19,339	\$ 35,253
Balance at October 31, 2021	\$ 13,714	\$ 2,517	\$ 897	\$ 108,456	\$ 125,584

6. Lease Commitment:

The Company's head office, located at 789 Don Mills Road, Suite 700, Toronto, Ontario M3C 1T5, is leased and considered to be a right-of-use asset. On March 1, 2021 the lease was amended with the expiry date extended to March 31, 2024 with no renewal term. Lease payments (including the Company's share of property taxes, operating costs, utilities and extra services) were \$43,891 (2020- \$44,879).

The lease liability has been measured by discounting future lease payments at the incremental borrowing rate at March 1, 2021. The incremental borrowing rate applied was determined to be 5.0% per annum for the lease and represents the Company's best estimate of the rate of interest that it would expect to pay to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in the current economic environment. As a result, the Company recorded an increase in capital assets, right of use asset, of \$134,634 and an increase in lease

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

liability of \$134,634. The carrying value included as part of property and equipment as at October 31, 2021 is \$108,456 (2020 - \$19,339). The lease liability has been broken down between current and non-current amounts. The current lease liability as at October 31, 2021 is \$42,532 (2020 - \$18,704) and the non-current lease liability is \$66,915 (2020 – nil).

The following details the changes in the lease liability for the year ended October 31, 2021 and 2020:

Balance, November 1, 2019 upon adoption of IFRS 16	\$	63,583
Interest expense		2,165
Undiscounted contractual lease payments made		(47,044)
Balance, October 31, 2020	\$	18,704
Addition of new premise lease		134,634
Interest expense		3,638
Undiscounted contractual lease payments made		(47,529)
Balance, October 31, 2021	\$	109,447

Future undiscounted contractual lease payments required through to the end of the lease on March 31, 2024 are as follows:

2022	\$	48,095
2023		48,878
2024		20,501

7. Debenture:

On January 24, 2020, the Company agreed with the holders of the Debentures in the Company at the time to redeem all of the Debentures outstanding without any prepayment penalty and issue new secured Debentures ("New Debentures") under the same terms and conditions of the previously amended Debentures, other than the maturity date was extended to April 24, 2021.

In connection with the issuance of the New Debentures the Company cancelled the original 800,000 common share purchase warrants issued and issued an aggregate of 800,000 new common share purchase warrants. Each such warrant is exercisable at any time prior to April 24, 2021 into one common share in the capital of the Company at an exercise price of \$0.13 per share.

The Company agreed to redeem the New Debentures with the holders of the New Debentures prior to the maturity date of April 24, 2021 redeeming \$200,000 principal amount of the New Debentures on October 5, 2020 ("Settlement 1") and the remaining \$200,000 on October 14, 2020 ("Settlement 2").

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

Pursuant to Settlement 1, based on the quoted market price of the shares at the time of settlement, the Company issued 416,667 common shares of the Company at a price of \$0.24 per common share for a total of \$100,000 and paid \$100,000 in cash plus accrued interest.

Pursuant to Settlement 2, based on the quoted market price of the shares at the time of settlement, the Company issued 350,000 common shares of the Company at a price of \$0.21 per common share for a total of \$74,000, 100,000 common share purchase warrants at a deemed price of \$0.26 per warrant for a total of \$26,000 with each warrant entitling the holder to acquire one common share in the capital of the Company at an exercise price of \$0.35 per share until October 14, 2022, and paid \$100,000 in cash plus accrued interest.

Accretion charges on the liability component of the debentures of the Company for the year ended October 31, 2020 were \$30,997 and were calculated using the discount rate of 20% and have been recorded in the statement of operations.

The following details the changes in the debenture for the year ended October 31, 2020:

Balance, October 31, 2019	\$ 390,703
Accretion charges	30,997
Equity portion of new debentures	(21,700)
Settlement, cash paid	(200,000)
Settlement, common shares and warrants	(200,000)
Balance, October 31, 2020	\$ -

8. Shareholders' Equity:

(a) Share capital authorized, issued and outstanding:

	2021	2020
Authorized:		
50,000 Series A preference shares		
Unlimited preference shares, issuable in series		
Unlimited common shares		
Issued: 94,451,221		
common shares		
(2020 – 91,393,973)	\$ 43,963,582	\$ 43,395,752

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

The following details the changes in issued and outstanding shares for the years ended October 31, 2021 and 2020.

	Common shares	
	Number	Amount
Balance, October 31, 2019	80,235,472	\$ 41,414,233
Private placement (note 8 (a)(i))	1,683,334	120,029
Exercise of warrants (note 8 (a)(ii))	5,258,500	1,211,540
Exercise of compensation options (note 8 (a)(iii))	1,200,000	239,200
Exercise of debenture warrants (note 8 (a)(iv))	400,000	62,850
Redemption of debenture (note 8 (a)(v))	766,667	174,000
Exercise of stock options (note 8 (a)(vi))	1,850,000	173,900
Balance, October 31, 2020	91,393,973	\$ 43,395,752
Exercise of warrants (note 8 (a)(vii))	1,612,332	386,960
Exercise of compensation options (note 8 (a)(viii))	184,916	44,380
Exercise of debenture warrants (note 8 (a) (ix))	400,000	62,850
Exercise of stock options (note 8 (a)(x))	860,000	73,640
Balance, October 31, 2021	94,451,221	\$ 43,963,582

(i) Private Placement:

On May 29, 2020, the Company completed a financing issuing by way of a private placement of 1,683,334 units at a price of \$0.12 per unit for gross proceeds of \$202,000. Each unit consists of one common share and one-half share purchase warrant. Each whole warrant entitles the holder to acquire one common share for \$0.15 at any time within 24 months of closing. As compensation for a portion of the financing a finders' fee was paid whereby 46,667 compensation warrants were granted. Each warrant entitles the holder to purchase one common share of the Company at a price of \$0.12 at any time within 24 months of closing. The fair value of each share purchase warrant and compensation warrant was estimated at the grant date using the Black-Scholes option pricing model, using the following assumptions: risk-free interest rate of 1.5%, expected volatility of 150%, expected life of the warrants of 2 years and 0% expected dividend yield. The fair value of the share purchase warrants and the compensation warrants was estimated to be \$0.08 and \$0.09 per warrant respectively.

(ii) Exercise of warrants:

There were 5,000,000 warrants exercised that were issued as part of a private placement completed on September 19, 2018 for cash proceeds of \$750,000. In addition, the fair value of the warrants, as estimated on date of grant, was \$400,000 which has been reclassified from warrants to share capital as a result of the exercise.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

There were 208,500 warrants exercised that were issued as part of the private placement completed on July 29, 2019 for cash proceeds of \$31,275. In addition, the fair value of the warrants, as estimated on date of grant, was \$18,765 which has been reclassified from warrants to share capital as a result of the exercise.

There were 50,000 warrants exercised that were issued as part of the private placement completed on May 29, 2020 for cash proceeds of \$7,500. In addition, the fair value of each warrant, as estimated on date of grant, was \$4,000 which has been reclassified from warrants to share capital as a result of the exercise.

(iii) Exercise of compensation options:

There were 800,000 compensation options exercised that were issued as part of a private placement completed on September 19, 2018 resulting in the issuance of 800,000 common shares and 400,000 warrants, which were simultaneously exercised for 400,000 common shares. Cash proceeds received upon exercise were \$140,000. In addition, the fair value of the compensation options, as estimated on date of grant, was \$99,200 which has been reclassified from compensation options to share capital as a result of the exercise.

(iv) Exercise of debenture warrants:

There were 400,000 debenture warrants exercised for cash proceeds of \$52,000. In addition, the fair value of the debenture warrants, as estimated on date of grant, was \$10,850 which has been reclassified from warrants to share capital as a result of the exercise.

(v) Redemption of debenture:

As part of the redemption of the debenture pursuant to settlement 1 and settlement 2 the Company issued 766,667 common shares at an estimated fair value of \$174,000 and 100,000 common share purchase warrants ("Warrants") at an estimated fair value of \$0.26 per Warrant. Each Warrant entitles the holder to acquire one common share in the capital of the Company at an exercise price of \$0.35 per share until October 14, 2022. The fair value of the common shares was based on the quoted market price of the Company's shares on the dates of settlement. The fair value of the Warrants was estimated at the grant date using the Black-Sholes option pricing model, using the following assumptions: risk-free interest rate of 1.5%, expected volatility of 161%, expected life of the Warrants of 2 years and 0% expected dividend yield.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

(vi) Exercise of stock options:

There were 1,850,000 stock options exercised pursuant to the Company's employee stock option plan at an average exercise price of \$0.05. Total cash proceeds were \$92,500. In addition, \$81,400 of stock based compensation had been previously recorded for the exercised stock options and has been reclassified from contributed surplus to share capital.

(vii) Exercise of warrants:

There were 1,612,332 warrants exercised that were issued as part of a private placement completed on July 29, 2019 for cash proceeds of \$241,850. In addition, the fair value of the warrants, as estimated on date of grant, was \$145,110 which has been reclassified from warrants to share capital as a result of the exercise.

(viii) Exercise of compensation options:

There were 184,916 compensation options exercised that were issued as part of a private placement completed on July 29, 2019 for cash proceeds of \$27,738. In addition, the fair value of the compensation options, as estimated on date of grant, was \$16,642 which has been reclassified from warrants to share capital as a result of the exercise.

(ix) Exercise of debenture warrants:

There were 400,000 debenture warrants exercised for cash proceeds of \$52,000. In addition, the fair value of the debenture warrants, as estimated on date of grant, was \$10,850 which has been reclassified from warrants to share capital as a result of the exercise.

(x) Exercise of stock options:

There were 860,000 stock options exercised pursuant to the Company's employee stock option plan at an average exercise price of \$0.05. Total cash proceeds were \$43,500. In addition, \$30,140 of stock based compensation had been previously recorded for the exercised stock options and has been reclassified from contributed surplus to share capital.

(b) Employee option plan:

The Company maintains a share option plan (the "Plan") for the benefit of management, directors, officers, contractors and employees. The Plan is a "rolling" stock option plan, pursuant to which the maximum number of common shares that may be reserved for issuance under outstanding stock options will be 10% of the Company's issued and outstanding common shares, as constituted on the date of any grant of options under the Plan.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

Options are granted under the Plan at the discretion of the Board of Directors at exercise prices determined as the trading prices of the Company's common shares on the TSX-V on the day preceding the effective date of the grant. In general, options granted under the Plan vest over the period of up to a maximum of five years from the grant date and expire by no later than the fifth anniversary of the date of grant.

Changes in outstanding options were as follows:

	Number	Weighted average exercise price
Options outstanding, October 31, 2019	6,235,000	\$ 0.06
Granted	700,000	0.15
Exercised	(1,850,000)	0.05
Options outstanding, October 31, 2020	5,085,000	\$ 0.08
Granted	940,000	0.36
Exercised	(860,000)	0.05
Expired	(250,000)	0.08
Options outstanding, October 31, 2021	4,915,000	\$ 0.14

The following table summarizes information about stock options outstanding at October 31, 2021:

Range of exercise prices	Options outstanding			Options exercisable	
	Number outstanding	Weighted average remaining contractual life (years)	Weighted average exercise price	Number exercisable	Weighted average exercise price
\$0.05 to \$0.07	2,335,000	1.1	\$ 0.07	2,335,000	\$ 0.07
\$0.10	1,540,000	2.0	\$ 0.10	1,240,000	\$ 0.10
\$0.36 to \$0.42	1,040,000	3.5	\$ 0.37	250,000	\$ 0.38
	4,915,000	1.9	\$ 0.14	3,825,000	\$ 0.10

The average grant date fair value of options granted during 2021 was \$0.36 (2020 - \$0.15). The fair value of each option granted has been estimated on the date of grant using the Black-Scholes fair value option-pricing model with the following assumptions used for grants for the year ended October 31, 2021: expected dividend yield of nil (2020 - nil), expected volatility of between 160% and 165% (2020 - between 166% and 176%), weighted average risk-free interest rate of 1.5% (2020 - 1.5%) and expected lives of four years (2020 - four years).

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

Details of the stock options granted for the year ended October 31, 2021 and 2020 follows:

Date granted	Expiry date	Number granted	Exercise price	Vesting
17-Mar-20	17-Mar-24	600,000	\$ 0.10	300,000 on 17-Sept-21 300,000 on 17-Mar-21
09-Oct-20	09-Oct-24	100,000	\$ 0.42	50,000 on 09-Oct-21 50,000 on 09-Oct-22
Granted in 2020		700,000		
12-Jan-21	12-Jan-25	200,000	\$ 0.38	50,000 on 12-Apr-21 100,000 on 12-Jul-21 50,000 on 12-Jan-22
09-Jun-21	09-Jun-25	740,000	\$ 0.36	185,000 on each of: 09-Dec-21 09-Jun-22 09-Dec-22 09-Jun-23
Granted in 2021		940,000		

Stock option expense for the year ended October 31, 2021 was \$202,801 (2020 - \$112,390).

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

(c) Warrants:

The following details the changes in the share purchase warrants for the years ended October 31, 2021 and 2020.

	Number	Amount	Weighted average exercise price
Balance, October 31, 2019	7,805,748	\$ 598,247	\$ 0.14
Warrants issued on private placement (note 8(a)(i))	841,667	67,333	0.15
Compensation warrants issued on private placement (note 8(a)(i))	46,667	4,200	0.12
Exercise of warrants (note 8(a) (ii))	(5,258,500)	(422,765)	0.15
Exercise of debenture warrants (note 8(a)(iv))	(400,000)	(10,850)	0.13
Warrants issued on redemption of debenture (note 8(a)(vi))	100,000	26,000	0.35
Cancelled during the year (note 7)	(800,000)	(17,730)	0.10
Equity portion of new debenture (note 7)	800,000	21,700	0.13
Balance, October 31, 2020	3,135,582	\$ 266,135	\$ 0.15
Exercise of warrants (note 8 (a) (vii))	(1,612,332)	(145,110)	0.15
Exercise of compensation options (note 8 (a) (viii))	(184,916)	(16,642)	0.15
Exercise of debenture warrants (note 8 (a)(ix))	(400,000)	(10,850)	0.13
Balance, October 31, 2021	938,334	\$ 93,533	\$ 0.15

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

The following table summarizes information about warrants outstanding at October 31, 2021:

	Exercise price	Number outstanding	Weighted average remaining contractual life (years)	Weighted average exercise price
Warrants issued on settlement of debenture (note 8 (a) (v))	0.35	100,000	0.95	0.35
Warrants issued on private placement (note 8(a)(i))	0.15	791,667	0.58	0.15
Compensation warrants issued on private placement (note 8(a)(i))	0.12	46,667	0.58	0.12
		938,334	0.62	\$ 0.15

9. Revenues:

The significant categories of revenue recognized during the year are as follows:

	2021	2020
Royalty, development fees and maintenance	\$ 864,583	\$ 497,050
Subscription fees	20,762	24,741
	\$ 885,345	\$ 521,791

10. Loss per Common Share:

The computations for basic and diluted loss per share are as follows:

	2021	2020
Loss for the year	\$ (656,847)	\$ (657,168)
Weighted average number of common shares outstanding:		
Basic	92,788,400	81,720,040
Diluted	92,788,400	81,720,040
Loss per common share:		
Basic	\$ (0.01)	\$ (0.01)
Diluted	(0.01)	(0.01)

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

As the Company is in a loss position for the years ended October 31, 2021 and 2020, the inclusion of options and warrants in the calculation of diluted earnings per share would be anti-dilutive, and accordingly, were excluded from the diluted loss per share calculation.

11. Change in Non-Cash Operating Working Capital:

	2021	2020
Accounts receivable	\$ (2,533)	\$ (106,919)
Prepaid expenses and other assets	(6,400)	(14,219)
Accounts payable and accrued liabilities (note 15)	31,243	10,149
Deferred revenue	(1,177)	(1,228)
	\$ 21,133	\$ (112,217)

12. Income Taxes:

The reconciliation of the income tax expense at the currently enacted tax rates for the years ended October 31, 2021 and 2020 is as follows:

Tax rate reconciliation:

	2021	2020
Loss for the year and comprehensive loss	\$ (656,847)	\$ (657,168)
Tax calculated at the 26.5% (2020 - 26.5%) enacted rate	\$ (174,000)	\$ (174,000)
Non-deductible expenses and permanent differences	44,000	30,000
Benefit of temporary differences and tax losses not recognized	130,000	144,000
Total income taxes recognized in net income	\$ -	\$ -

Unrecognized deferred tax assets:

The benefit related to deferred tax temporary differences have not been recognized in respect of the following items:

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

	2021	2020
Non-capital loss carry-forwards	\$ 13,019,000	\$ 12,999,000
Research and development deduction pool	12,476,000	12,000,000
Financing costs	80,000	118,000
Property and equipment	5,000	5,000

As at October 31, 2021, the Company had an unclaimed pool of scientific research and experimental development costs of approximately \$12,476,000, which can be carried forward indefinitely as a deduction against future taxable income, and investment tax credits of approximately \$3,235,000, which can be utilized to reduce taxes payable in years up to 2041. The tax benefits have not been recorded in the consolidated financial statements because it is not probable that future taxable profit will be available against which the Company can use the benefits.

The Company had unused tax loss carry forwards which expire as follows:

2026	\$ 872,000
2027	1,368,000
2028	783,000
2029	553,000
2030	639,000
2031	2,201,000
2032	1,063,000
2033	2,221,000
2034	1,290,000
2035	1,012,000
2036	509,000
2038	228,000
2040	260,000
2041	20,000
Total unused tax losses	\$ 13,019,000

13. Segmented Information:

The Company currently operates in one business segment, which is the development and marketing of its remote access software and its cryptographic software. The Company markets its products primarily in the United States, Asia/Pacific and Canada.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

Revenue attributable to geographic location based on the location of the customer is as follows:

	2021	2020
United States	\$ 11,185	\$ 14,860
Canada	9,577	9,881
Asia/Pacific	864,583	497,050
	\$ 885,345	\$ 521,791

Substantially all of the Company's identifiable assets as at October 31, 2021 and 2020 are located in Canada.

14. Related Party Transactions:

The remuneration of directors and other key management personnel of the Company during the years ended October 31, 2021 and 2020 was as follows:

	2021	2020
Salaries and contractor fees	\$ 235,000	\$ 227,500
Stock-based compensation	107,498	110,594
Total	\$ 342,498	\$ 338,094

The Company's President and Chief Executive Officer ("CEO") invoices the Company for his services that pertain to research and development pursuant to a contractor agreement. Fees paid under this agreement during 2021 were \$66,000 (2020 - \$66,000) and have been included in research and development expenses and are included in the salaries and contractor fees amounts in the above table. In addition, the CEO received a salary for 2021 of \$84,000 (2020 - \$84,000) which has been recorded in selling, general and administrative expenses, and is included in the salaries and contractor fees amounts in the above table.

The CEO participated in the private placement that closed on May 29, 2020 subscribing for a total of 500,000 units of the offering at the same price and under the terms as other participants. The total amount paid by the CEO for the units was \$60,000.

Salary and contractor fees included in the above table owing to directors and other key management personnel and so included in accounts payable and accrued liabilities at October 31, 2021 is \$12,300 (2020 - \$12,300). They are unsecured, non-interest bearing with no fixed terms of payment and were paid subsequent to the end of the year.

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

15. Contingencies:

The Company is engaged in legal actions from time to time arising in the ordinary course of business. None of these actions, individually or in the aggregate, is expected to have a material adverse effect on the consolidated financial position or results of operations.

On October 7, 2020 the Company entered into a non-binding agreement for a drawdown equity facility with a private equity firm. The agreement provides for equity private placement offerings up to \$5,000,000 in units of the Company, with each unit consisting of one common share and one-half of one common share purchase warrant, to be conducted in drawdowns of up to \$250,000 per tranche over a period of 24 months with the timing of each tranche to be made by the Company at its sole discretion. The amount and terms of each tranche will be subject to the mutual agreement of the Company and the investor. As at October 31, 2021 and 2020, no placements had been made.

In March 2020, the COVID-19 outbreak was declared a global pandemic by the World Health Organization. The situation is dynamic and the ultimate duration and magnitude of the impact on the economy, capital markets and the Company's financial position cannot be reasonably estimated at this time. The Company is monitoring developments and will adapt its business plans accordingly. The actual and threatened spread of COVID-19 globally could adversely impact the Company's operations and ability to raise capital. To date the Company has been able to adapt its operations thereby minimizing the impact from the pandemic.

16. Operating Expenses:

The Company presents functional consolidated statements of operations in which expenses are aggregated according to the function to which they relate. The Company has identified the major functions as selling, general and administrative expenses; and research and development expenses. The following tables present the expenses based on their nature:

01 COMMUNIQUE LABORATORY INC.

Notes to Consolidated Financial Statements
(In Canadian dollars)

Years ended October 31, 2021 and 2020

2021				
	Selling, general and administration		Research and development	
				Total
Salaries, contractors, commissions and benefits	\$	343,009	\$	541,046
Stock-based compensation		202,801		-
Other operating expenses		295,218		73,173
	\$	841,028	\$	614,219
			\$	1,455,247
2020				
	Selling, general and administration		Research and development	
				Total
Salaries, contractors, commissions and benefits	\$	235,649	\$	361,943
Stock-based compensation		112,390		-
Other operating expenses		238,737		93,234
	\$	586,776	\$	455,177
			\$	1,041,953

17. Government Assistance:

- (a) The Canada Emergency Wage Subsidy ("CEWS") government program provides a wage subsidy of 75% for qualifying businesses. The purpose of the wage subsidy is to allow employers to re-hire workers that were previously laid off, and to continue to employ those who are already on payroll. For the year ended October 31, 2021, the Company has received approximately \$19,800 (2020 - \$38,800) as a wage subsidy under this program. This has been recognized in the consolidated statements of operations as a reduction to the related expenses.
- (b) The Canada Emergency Business Account ("CEBA") provides interest-free bank loans, guaranteed by the government of Canada, of up to \$60,000 to small businesses that qualify. The Company's loan payable consists of a \$60,000 CEBA loan that is interest free and repayable by December 31, 2022 with up to \$20,000 of the loan being forgiven conditional upon the Company repaying the full amount due of \$60,000 by maturity which is December 31, 2022. If these loans are not repaid by December 31, 2022, they will be extended for an additional 3-year term bearing an interest rate of 5% per annum and maturing on December 25, 2025. Management has assessed that it is likely the Company would be able to repay the balance of the loans by December 31, 2022 and accordingly, the total forgivable amount of \$20,000 has been recorded as government assistance income in 2021.